Marjorie C Gondré‐Lewis
Biographic Data
| ID | 7955971 |
|---|---|
| NAME | Marjorie C Gondré‐Lewis |
| GIVEN NAMES | Marjorie C |
| FAMILY NAME | Gondré‐Lewis |
| SIGNATURE | LEWIS M C G |
| AFFILIATIONS | Howard University |
| VERIFIED | No |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2018 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Since 1990, substantial evidence from association studies has identified the D(2) dopamine receptor (DRD2) gene as a factor in the development of alcoholism [1][2][3][4]. The DRD2 gene has also been linked to other substance use disorders, including dependencies on cocaine, nicotine, and opioids, as well as obesity [5][6][7][8][9][10][11]. Dopamine in the brain, often referred to as the "stressrelief molecule," plays a central role in managing st…
The Opioid Epidemic
Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans
Over years, the regular use of cannabis has substantially increased among young adults, as indicated by the rise in cannabis use disorder (CUD), with an estimated prevalence of 8. 3% in the United States. Research shows that exposure to cannabis is associated with hypodopaminergic anhedonia (depression), cognitive decline, poor memory, inattention, impaired learning performance, reduced dopamine brain response-associated emotionality, and increas…
Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors
reward deficiency syndrome (RDS), dopamine homeostasis, genetic addiction risk score (GARS), comprehensive analysis of reported drugs (CARD), precision addiction management (PAM)
No prominent works on this page.
Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors
reward deficiency syndrome (RDS), dopamine homeostasis, genetic addiction risk score (GARS), comprehensive analysis of reported drugs (CARD), precision addiction management (PAM)
Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans
Over years, the regular use of cannabis has substantially increased among young adults, as indicated by the rise in cannabis use disorder (CUD), with an estimated prevalence of 8. 3% in the United States. Research shows that exposure to cannabis is associated with hypodopaminergic anhedonia (depression), cognitive decline, poor memory, inattention, impaired learning performance, reduced dopamine brain response-associated emotionality, and increas…
The Opioid Epidemic
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Since 1990, substantial evidence from association studies has identified the D(2) dopamine receptor (DRD2) gene as a factor in the development of alcoholism [1][2][3][4]. The DRD2 gene has also been linked to other substance use disorders, including dependencies on cocaine, nicotine, and opioids, as well as obesity [5][6][7][8][9][10][11]. Dopamine in the brain, often referred to as the "stressrelief molecule," plays a central role in managing st…
Addiction (3 works) · Medicine (3 works) · Psychology (3 works) · Attention Deficit Hyperactivity Disorder (2 works) · Dopamine (2 works) · Prenatal Substance Exposure Effects (2 works) · Psychiatry (2 works) · Addictive behavior (1 work) · Agonist (1 work) · Anhedonia (1 work)